Greg Freiherr, Industry Consultant
Greg Freiherr, Industry Consultant

Greg Freiherr has reported on developments in radiology since 1983. He runs the consulting service, The Freiherr Group.

Blog | Greg Freiherr, Industry Consultant | Magnetic Resonance Imaging (MRI) | October 30, 2019

MRI: On the Cusp of Renewed Greatness?

After years of growing popularity, MRI usage fell sharply from 2016 to the next year. Then, in 2018, MRI rebounded, according to the Organization for Economic Cooperation and Development (OECD).

What’s going on with MRI? Once the darling of medical imaging, MRI had fallen on hard times. But those times didn’t last.

After years of growing popularity, MRI usage fell sharply from 2016 to the next year. Then, in 2018, MRI rebounded, according to the Organization for Economic Cooperation and Development (OECD). Whether that will continue this year and beyond is hard to say.

What we do know is that federal regulators have been targeting imaging – particularly the higher tech, more expensive modalities. Imaging reimbursements have been declining for years. But lately, the picture has been mixed.

Medicare rates held steady for hospital outpatient services throughout radiology in 2019 for hospitals and doctors, increasing by 1.35% as they did in 2018. But a shift is underway to bundle outpatient services into what are called APCs (Ambulatory Payment Classifications).

Meanwhile, some outpatient MRI providers are cutting prices. Smart MRI, for example, is advertising better pricing and, in a doff of the proverbial hat to the consumer, is advertising a “better patient experience,” as well.

The Power of Value

The decision by this chain of outpatient MRI centers aligns with value-driven medicine, which is advancing at the same time that providers, insurers – and, importantly, employers – have come to recognize that MRI delivers value. This could be very significant.

Companies – at least ones that look to the long term – recognize that MRI can help. Speaking at the annual meeting of the AHRA in July, an executive of The Advisory Board Company said: “We want our 25-year-old employee to get his MRI (when he hurts his back).” Better to treat that injury when it happens, he told me, rather than later on. “If he is our employee 25 years down the road, we don’t want to bear the cost of $50,000 for more advanced care,” he continued – certainly not when an MRI might have provided information that could have led to a resolution of the issue early on.

Gunslingers on the Rebound?

The Wild-West days of magnetic resonance imaging are gone. Those were in the 1980s, when outpatient MRI was roaring (largely because MR scanning was less expensive at clinics than in hospitals); and when the value of the modality was as evident as the images were startling. These times may be long ago but they may still be relevant.

One MRI convert told me back then that he had never seen anything like MR images. Now, decades later, just about everybody is familiar with MRI – doctors and nurses; parents and children; even sports fans who read about injured players’ knee scans.

With a slight twist, could history be repeating itself? Could MRI be in for a resurgence?

Potentially driving usage could be demand for the diagnosis of neuromuscular disease – as yet unproven but intuitively helpful as a diagnostic aid. Characterized by progressive muscle degeneration and weakness, each neuromuscular disease is individually rare. BUT…taken as a group, their incidence is common.

Many lack effective treatment with drugs fully approved for marketing. Magnetic resonance imaging and spectroscopy are showing increasing promise as an outcome measure in clinical trials for these diseases.

If this potential leads to drugs for disease treatment, the use of MR imaging and spectroscopy for diagnosis might accompany the marketing of these drugs. And then there are recent developments in cardiac MR, particularly as it relates to FFR (fractional flow reserve).

But even if such developments don’t drive MRI growth, the modality could be in for a growth spurt through the widespread adoption of value-medicine. Already we are seeing a lot of work being done on the underlying technology.

Future Products – Or Not?

Works in progress run the gamut from whole MRI systems to components designed to improve workflow. Some promise to bring data to mobile devices, such as cell phones and tablets. The question is whether these new ideas will turn into real products or if they are just hopeful embellishments of where technology might go. A lot is at stake.

The manufacturers of MRI equipment have to anticipate where markets are going, just as quarterbacks have to throw to where a receiver is going, not to where he has been. But they have to be careful. Niether can be taken in by head fakes.

For-profit companies eventually have to make a profit. And making the world a better place is not their top criterion. That is not to say profitable businesses don’t make the world better. They did so when it came to MRI and other high- tech -- as well as low-tech -- imaging modalities. (When was the last time you heard of a doctor recommending exploratory surgery?)

But imaging undeniably has made health care more expensive. Yes, heroic measures like exploratory surgery are seldom, if ever, done anymore. But that kind of surgery was never commonplace. And for good reason.

Not only were exploratory surgeries difficult for patients to bear physically, they added expense, gobbling up operating room and staff time, and incurring costs as patients were hospital-ridden for days or weeks. MRI, on the other hand, has been widely used, particularly in the United States, for decades.

In the mid-1980s, Medicare began reimbursing for its scans. Third party insurers followed suit. And the flood gates opened.

As often happens with any new technology, MRI reimbursements were high in those early days. Not surprisingly, the number of MRI scanners installed in the U.S. spiked n the following decades. But the number began to ebb as the market grew saturated and reimbursements declined. Still MRI remains popular.

In 2018, 119 MRI exams were performed per 1000 residents in the U.S., making America the second biggest user of MRI in the world, surpassed only by Germany, according to OECD.

Even though medical practice in the U.S. is changing, such that value – not reimbursement – is becoming the most important factor. But cost will remain an issue, because it will factor into the calculation of value.

And so, MRI has come to a fork in the road. It stands either on the cusp of renewed greatness or on the periphery of a bubble ready to burst. Or it could just stand there – paralyzed – at that fork.

Time – and the development of MR technology – will tell.

Related Content

#COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2 New studies use SIRD model to forecast COVID-19 spread; examine patient CT scans to correlate clinical features with mortality

Fig 1. A sample scoring on CT images of a 63-year-old woman from mortality group demonstrated a total score of 63. It was calculated as: for upper zone (A), 3 (consolidation) × 3 (50–75% distribution) × 2 (both right and left lungs) + 2 (ground glass opacity) ×1 (< 25% distribution) × 2 (both right and left lungs); for middle zone (B), 3 (consolidation) × 2 (25–50% distribution) × 2 (both right and left lungs) + 2 (ground glass opacity) × 2 (25–50% distribution) × 2 (both right and left lungs); for lower zone (C), 3 (consolidation) × (2 (25–50% distribution of the right lung) + 3 (50–75% distribution of the left lung)) + 2 (ground glass opacity) × (2 (25–50% distribution of the right lung) + 1 (< 25% distribution of the left lung)) Yuan et al, 2020 (CC BY 4.0)

News | Coronavirus (COVID-19) | April 01, 2020
April 1, 2020 — A new study, ...
#COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2 Company emphasizes faster, more advanced CTs, making imaging easier for COVID-19 patients
News | Computed Tomography (CT) | April 01, 2020
April 1, 2020 — United Imaging, a global leader in advanc
#COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2 A brief article from Henry Ford Health System in Detroit, published today in Radiology, reports on the first presumptive case of COVID-19–associated acute necrotizing hemorrhagic encephalopathy.

A, Image from noncontrast head CT demonstrates symmetric hypoattenuation within the bilateral medial thalami (arrows). B, Axial CT venogram demonstrates patency of the cerebral venous vasculature, including the internal cerebral veins (arrows). C, Coronal reformat of aCT angiogram demonstrates normal appearance of the basilar artery and proximal posterior cerebral arteries. Image courtesy of the Radiological Society of North America (RSNA)

News | Coronavirus (COVID-19) | March 31, 2020
March 31, 2020 — A brief article fr
#COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2 Doctor in our hospital is using this intelligent system for accurate diagnosis

Doctor in our hospital is using this intelligent system for accurate diagnosis. (Photo: Business Wire)

News | Artificial Intelligence | March 31, 2020
March 31, 2020 — The Intelligent Evalua...
#COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2
News | Coronavirus (COVID-19) | March 31, 2020
March 31, 2020 — In a...
AI tool predicts which patients newly infected with COVID-19 will eventually develop severe respiratory disease #COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2
News | Artificial Intelligence | March 31, 2020
March 31, 2020 — An artificial intelligence tool accurately predicted which patients newly infected with the...
RSNA's open data repository will compile images and correlative data to create a comprehensive source for COVID-19 research and education efforts #COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2
News | Coronavirus (COVID-19) | March 30, 2020
March 30, 2020 — The medical imaging community around the world is uniting to help address the...
Phase III response to the COVID-19 public health emergency (PHE) CARES Act signed into law #CARESAct #COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2
Feature | Coronavirus (COVID-19) | March 28, 2020 | By Melinda Taschetta-Millane
On March 27, the House of Representatives approved a historic $2
AI vendor Infervision's InferRead CT Pneumonia software uses artificial intelligence-assisted diagnosis to improve the overall efficiency of the radiology department. It is being developed in China as a high sensitivity detection aid for novel coronavirus pneumonia (COVID-19). #COVID19 #coronavirus #SARScov2

AI vendor Infervision's InferRead CT Pneumonia software uses artificial intelligence-assisted diagnosis to improve the overall efficiency of the radiology department. It is being developed in China as a high sensitivity detection aid for novel coronavirus pneumonia (COVID-19).

Feature | Coronavirus (COVID-19) | March 27, 2020 | Jilian Liu, M.D., HIMSS Greater China
An older couple walked into the Hubei Provincial Hospital of Integrated Chinese and Western Medicine near their neigh